Global News

AstraZeneca, Broad Institute partner on discovery of antibacterial and antiviral agents

Wednesday, September 12, 2012 09:09 AM

AstraZeneca and the Broad Institute in Cambridge, Mass., have formed a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs.

More... »

Minervation launches Mental Elf app

Tuesday, September 11, 2012 11:28 AM

Oxford University spin-out company Minervationhas developed the Mental Elf iPhone app, which provides users a daily update of mental health research, policy and guidance.

More... »

Eckert & Ziegler acquires Vitalea Science

Tuesday, September 11, 2012 11:25 AM

Germany-based Eckert & Ziegler Strahlen- und Medizintechnik, through its Californian subsidiary Eckert & Ziegler Isotope Products (EZIP), has agreed to purchase all stock and assets of Vitalea Science. Vitalea Science is a bioanalytical CRO that provides services to researchers and clinicians in drug development supported by validated Accelerator Mass Spectrometry (AMS) technologies.

More... »

MonitorForHire.com releases new mobile app

Tuesday, September 11, 2012 11:23 AM

Conshohocken, Penn.-based MonitorForHire.com, a patented, web-enabled management tool for locating and contracting independent clinical research monitors, has released a free mobile application. The app, designed for clinical research monitors registered with MonitorForHire.com, is available via Apple's App Store and Android's Google Play Store.

More... »

Report: Investment in social media analytics software and services growing rapidly

Monday, September 10, 2012 03:06 PM

IDC Health Insights released a new IDC MarketScape report which helps end users evaluate the top nine leading social media analytics software and service vendors that currently address the pharmaceutical industry.

More... »

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

Icon expands U.S. and U.K. bioanalytical labs

Monday, September 10, 2012 09:48 AM

Icon,a global provider of outsourced development services, is expanding its U.S. and U.K. bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.

Icon has increased its bioanalytical laboratories in Whitesboro, N.Y., and Manchester, U.K., by 7,000 and 4,000 square feet, respectively. The expansions allow Icon to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays.

More... »

ERT launches enhanced platform to streamline data collection, analysis and processing

Friday, September 7, 2012 11:57 AM

ERT, a global technology-driven provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials.

More... »

SFJ, Pfizer collaborate on phase III trial of dacomitinib in lung cancer

Friday, September 7, 2012 11:21 AM

The SFJ Pharmaceuticals Group (SFJ), a global drug development group of companies, has entered into a collaborative development agreement with Pfizer to conduct a phase III clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).

More... »

Faster approval: oncology drugs in the U.S., non-oncology drugs in the E.U.

Friday, September 7, 2012 10:45 AM

Approval times for new oncology drugs in the U.S. during the last decade were shorter than approval times for non-oncology products, while the reverse was the case in the E.U., according to a study recently completed by the Tufts Center for the Study of Drug Development.

More... »